2023 - Research.com Microbiology in Netherlands Leader Award
2022 - Research.com Microbiology in Netherlands Leader Award
Fellow of the European Confederation of Medical Mycology (ECMM)
Paul E. Verweij mainly investigates Microbiology, Aspergillus fumigatus, Aspergillosis, Voriconazole and Itraconazole. His research is interdisciplinary, bridging the disciplines of Genotype and Microbiology. His work deals with themes such as Fungi imperfecti, Azole, Azole resistance and Drug resistance, which intersect with Aspergillus fumigatus.
Paul E. Verweij interconnects Internal medicine, Mycosis and Aspergillus in the investigation of issues within Aspergillosis. His work carried out in the field of Voriconazole brings together such families of science as Pharmacology and Chronic granulomatous disease. Paul E. Verweij usually deals with Itraconazole and limits it to topics linked to Fluconazole and Amphotericin B deoxycholate.
His primary areas of investigation include Microbiology, Aspergillus fumigatus, Aspergillosis, Voriconazole and Aspergillus. His study in Microbiology concentrates on Itraconazole, Amphotericin B, Antifungal, Broth microdilution and Fungi imperfecti. His work focuses on many connections between Aspergillus fumigatus and other disciplines, such as Azole, that overlap with his field of interest in Fungicide and Gene.
His studies in Aspergillosis integrate themes in fields like Pathology, Internal medicine, Mycosis and Intensive care medicine. Paul E. Verweij has researched Voriconazole in several fields, including Echinocandin and Pharmacology. His studies deal with areas such as Galactomannan and Chronic pulmonary aspergillosis as well as Aspergillus.
Paul E. Verweij mostly deals with Aspergillosis, Aspergillus fumigatus, Microbiology, Aspergillus and Azole. His Aspergillosis research incorporates elements of Internal medicine, Hematological malignancy, Disease, Posaconazole and Intensive care medicine. His Aspergillus fumigatus study combines topics from a wide range of disciplines, such as Genetics, Gene, Genotype, Fungicide and Azole resistance.
His Microbiology research integrates issues from Cystic fibrosis and Agar. His work in Aspergillus addresses subjects such as Chronic pulmonary aspergillosis, which are connected to disciplines such as Mutation. The concepts of his Voriconazole study are interwoven with issues in Amphotericin B, Mortality rate, Luliconazole, Susceptibility testing and Broth microdilution.
His primary areas of study are Aspergillus fumigatus, Aspergillosis, Microbiology, Voriconazole and Internal medicine. His Aspergillus fumigatus research is multidisciplinary, relying on both Antifungal drug, Itraconazole, Azole and Genotype. His Aspergillosis research incorporates themes from Coinfection, Ventilator-associated pneumonia, Posaconazole and Aspergillus flavus.
His Microbiology study combines topics in areas such as Infection control, Fungicide and Agar. The various areas that Paul E. Verweij examines in his Voriconazole study include Disease and Intensive care medicine. His research investigates the connection with Internal medicine and areas like Galactomannan which intersect with concerns in Allergy, Transplantation, Multicenter study and Gastroenterology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
O.A. Cornely;M. Bassetti;T. Calandra;J. Garbino.
Clinical Microbiology and Infection (2012)
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
J. Peter Donnelly;Sharon C. Chen;Carol A. Kauffman;William J. Steinbach.
Clinical Infectious Diseases (2020)
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
A. J. Ullmann;J. M. Aguado;S. Arikan-Akdagli;D. W. Denning.
Clinical Microbiology and Infection (2018)
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts.
J.L. Rodriguez-Tudela;M.C. Arendrup;F. Barchiesi;J. Bille.
Clinical Microbiology and Infection (2008)
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism.
Eveline Snelders;Henrich A. L van der Lee;Judith Kuijpers;Anthonius J. M. M Rijs.
PLOS Medicine (2008)
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
Paul E Verweij;Eveline Snelders;Gert H J Kema;Emilia Mellado.
Lancet Infectious Diseases (2009)
Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis
Monique A S H Mennink-Kersten;J Peter Donnelly;Paul E Verweij.
Lancet Infectious Diseases (2004)
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
O.A. Cornely;S. Arikan-Akdagli;E. Dannaoui;A.H. Groll.
Clinical Microbiology and Infection (2014)
A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A Alterations
E. Mellado;G. Garcia-Effron;L. Alcázar-Fuoli;W. J. G. Melchers.
Antimicrobial Agents and Chemotherapy (2007)
Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study.
Alexander F A D Schauwvlieghe;Bart J A Rijnders;Nele Philips;Rosanne Verwijs.
The Lancet Respiratory Medicine (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: